Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 9/20 | 0.54 |
| ▸ | MAOB | P27338 | 9/20 | 0.54 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17362038 | 0.88 | MAOA (0.53) | MAOAMAOBPRKCIMAPK14CYP2A6 | |
| SCHEMBL315261 | 0.84 | GRM5 (0.56) | MAOAMAOBPRKCIMAPK14CYP2A6 | |
| SCHEMBL2513812 | 0.84 | MAOA (0.42) | MAOAMAOBPRKCIMAPK14CYP2A6 | |
| SCHEMBL17361535 | 0.82 | MAOA (0.47) | MAOAMAOBPRKCIMAPK14CYP2A6 | |
| SCHEMBL641843 | 0.82 | MAOA (0.40) | MAOAMAOBMAPK14KDM4CKDM4E | |
| SCHEMBL17362073 | 0.80 | PTGS2 (0.46) | MAOAMAOBPRKCIMAPK14CYP2A6 | |
| SCHEMBL30558451 | 0.80 | PTGS2 (0.46) | MAOAMAOBPRKCIMAPK14CYP2A6 | |
| SCHEMBL10126099 | 0.80 | NPC1 (0.43) | KDM4C | |
| SCHEMBL315877 | 0.79 | MAOA (0.61) | MAOAMAOBPRKCIMAPK14CYP2A6 | |
| SCHEMBL17361968 | 0.79 | MAOA (0.53) | MAOAMAOBPRKCICYP2A6GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111909083-B | Inhibitors of histone demethylase | 赛尔基因昆蒂赛尔研究公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3160952-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3160952-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3741749-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3741749-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3738960-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3738960-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| CN-111909083-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-106660982-B | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-09-08 | — | — | CN | disclosed |
| US-10385047-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20120323040-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | DURKIN KIERAN (US) | 2012-12-20 | — | — | US | disclosed |
| US-8119842-B2 | Process for synthesis of amino-methyl tetralin derivatives | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119842-B2 | Process for synthesis of amino-methyl tetralin derivatives | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119842-B2 | Process for synthesis of amino-methyl tetralin derivatives | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2379491-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010069778-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010069778-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | PKN2, CCND2, PRMT1 | MAOA 2897/4885MAOB 2165/4885PRKCI 3208/4885 |
| US-20120323040-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | PKN2, CCND2, PRMT1 | MAOA 2990/4885MAOB 2178/4885PRKCI 3152/4885 |
| US-10385047-B2 | Histone demethylase inhibitors | KDM1B, KDM6A, KDM1A | MAOA 404/4885MAOB 517/4885PRKCI 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.